Patents Assigned to Foundation for Biomedical Research and Innovation
-
Publication number: 20240150421Abstract: A novel interleukin-18 (IL-18) variant and a pharmaceutical composition using the same, which relates to a human IL-18 variant including (i) mutations of cysteine at positions 38, 68, 76, and 127 into serine and (ii) mutations of glutamic acid at position 6 and lysine at position 53 into alanine relative to an amino acid sequence of wild-type human IL-18, where the variant further includes (iii) at least one additional mutation, and a pharmaceutical composition containing the human IL-18 variant.Type: ApplicationFiled: February 9, 2022Publication date: May 9, 2024Applicants: NAGASAKI UNIVERSITY, Foundation for Biomedical Research and Innovation at Kobe, National Institutes for Quantum Science and TechnologyInventors: Yoshimasa TANAKA, Shun SAKURABA
-
Patent number: 11744858Abstract: The present invention provides a sufficiently effective medicine for treatment and/or prevention of ischemic diseases, without performing isolation of therapeutic cells or removal of deleterious cells from blood cells/hemocytes. The blood cells and/or the hemocytes are subjected to the action of a saccharide. The saccharide is a monosaccharide, a disaccharide, a trisaccharide, a polysaccharides, or a copolymer containing a monosaccharide, a disaccharide, or a trisaccharide as a component. The saccharide is a copolymer of sucrose and epichlorohydrin.Type: GrantFiled: March 18, 2016Date of Patent: September 5, 2023Assignee: Foundation for Biomedical Research and Innovation at KobeInventors: Akihiko Taguchi, Kenichi Yamahara, Yukiko Niino
-
Publication number: 20230190816Abstract: The effect of physical exercise performed on a physical function of a subject with an irreversibly reduced physical function is promoted. Bone marrow mononuclear cells, CD34-positive cells, CD133-positive cells, or stem cells are contained. The central and peripheral nerves communicate intimately with each other. When these cells are administered to a subject, and the subject performs an appropriate physical exercise, the reduced physical function can be dramatically improved. The physical exercise .is, for example, physical exercise that stimulates both of brain and peripheral nerves based on the interactive biofeedback theory. Thus, for example, when bone marrow mononuclear cells are administered to a patient with a sequela of cerebral infarction, and the patient performs an appropriate physical exercise, the effect of functional recovery from the sequela of the cerebral infarction is promoted.Type: ApplicationFiled: November 26, 2020Publication date: June 22, 2023Applicant: Foundation for Biomedical Research and Innovation at KobeInventors: Akihiko TAGUCHI, Yuko OGAWA, Yuka OKINAKA, Masanori FUKUSHIMA, Atsuo YAMANAKA
-
Publication number: 20230183347Abstract: A novel use of agonist to PD-1 is developed. Provided is a pharmaceutical composition for treating or preventing Th2-mediated diseases, the composition comprising an effective amount of a PD-1 agonist.Type: ApplicationFiled: May 24, 2021Publication date: June 15, 2023Applicants: Foundation for Biomedical Research and Innovation at Kobe, National Institutes of Biomedical Innovation, Health and Nutrition, Meiji Seika Pharma Co., Ltd.Inventors: Tasuku Honjo, Akio Ohta, Masaki Tajima, Haruhiko Kamada, Satoshi Nagata, Kensuke Suzuki, Yuya Oshiro, Yosuke Tokumaru
-
Publication number: 20230021187Abstract: A substance that can be a substitute for amylospheroids (ASPD) and a method for analyzing ASPD are provided. Viewed from one aspect, the present disclosure relates to a substance in which amyloid-? protein (A?) is cross-linked with a cross-linking agent that has a spacer arm length of between 4 ? and 50 ? inclusive or a cross-linking agent that has, as a spacer arm, not less than 1 and not more than 13 groups that are an oxyethylene group(s) (—CH2CH2O—) and/or an oxypropylene group(s) (—CH2CH2CH3O—). Viewed from another aspect, the present disclosure relates to a method for analyzing ASPD using the substance as a reference material.Type: ApplicationFiled: November 18, 2020Publication date: January 19, 2023Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Minako HOSHI, Yoshie ARAI, Kiyotaka MACHIDA
-
Patent number: 11479754Abstract: A method for producing an epithelial cell sheet, comprising culturing cells derived from oral mucosal epithelial cells on a substrate in a serum-free medium, wherein the serum-free medium comprises (i) EGF protein or KGF protein, (ii) B-27 supplement, and (iii) a ROCK inhibitor.Type: GrantFiled: April 19, 2017Date of Patent: October 25, 2022Assignees: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Takahiro Nakamura, Shigeru Kinoshita, Seiichi Yokoo, Satoru Yamagami
-
Publication number: 20220265603Abstract: The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and/or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.Type: ApplicationFiled: June 24, 2020Publication date: August 25, 2022Applicants: NATIONAL HOSPITAL ORGANIZATION, NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Advanced Innovation Development Co., Ltd., FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Noriko ASAHARA, Takayuki INOUE, Masashi TANAKA, Masafumi IHARA, Satoshi SAITO
-
Publication number: 20220260580Abstract: The present invention relates to a method for evaluating the state of cell differentiation during the process of inducing differentiation of human induced pluripotent stem cells (iPS cells) into retinal pigment epithelial cells. The present invention further relates to a method for evaluating the state of cell differentiation during the process of inducing differentiation of human embryonic stem cells (ES cells) into retinal pigment epithelial cells.Type: ApplicationFiled: July 19, 2019Publication date: August 18, 2022Applicants: TOKYO ELECTRON LIMITED, SHIMADZU CORPORATION, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Keisuke HARA, Shinichi GOMI, Tomohisa NAGATA, Kenichi KAGAWA, Yasuhiro OSHIMA, Takashi SUZUKI, Masatoshi TAKAHASHI, Takako YAMAMOTO, Shin KAWAMATA
-
Patent number: 11389486Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: GrantFiled: July 11, 2019Date of Patent: July 19, 2022Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi
-
Publication number: 20220011297Abstract: A method may predict risk of onset of severe interstitial pneumonia caused by an immune checkpoint inhibitor to achieve a safe and highly effective cancer immunotherapy. Any one or more selected from: (a) cell count or proportion of V?2+?? T cells in peripheral blood mononuclear cells isolated from a subject; (b) cell count or proportion of V?2+?? T cells after antigenic stimulation in peripheral blood mononuclear cells isolated from a subject; (c) cell count or proportion of V?2+?? T cells in peripheral blood T cells isolated from a subject; and (d) cell count or proportion of V?2+?? T cells after antigenic stimulation in peripheral blood T cells isolated from a subject are measured, and the risk of onset of severe interstitial pneumonia is predicted by using the cell count or proportion as an index.Type: ApplicationFiled: October 1, 2019Publication date: January 13, 2022Applicants: NAGASAKI UNIVERSITY, Foundation for Biomedical Research and Innovation at KobeInventors: Yoshimasa TANAKA, Hiroaki SENJU, Hiroshi MUKAE, Masanori FUKUSHIMA
-
Patent number: 11219672Abstract: A cancer therapeutic agent according to an embodiment of the present invention contains, as active ingredients, IL-18 and one or more antibodies selected from the group consisting of an anti-PD-L1 antibody, an anti-PD-1 antibody, an anti-PD-L2 antibody, an anti-CTLA-4 antibody, an anti-CD25 antibody, an anti-CD33 antibody, and an anti-CD52 antibody.Type: GrantFiled: August 7, 2015Date of Patent: January 11, 2022Assignees: Medical Research and Development Corporation, Foundation for Biomedical Research and InnovationInventors: Haruki Okamura, Kyosuke Yamanishi, Wen Li
-
Publication number: 20210198307Abstract: The purpose of the present invention is to provide a method for producing active GcMAF more simply and at a high yield. The present invention is a method for producing active GcMAF comprising a step for culturing host cells which are transfected with a VDBP expression vector in serum-free medium. This culture is preferably a suspension culture. In addition, this method for producing active GcMAF is also characterized by not requiring an enzyme treatment step for deglycosylation.Type: ApplicationFiled: December 14, 2018Publication date: July 1, 2021Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Yo-ichi NABESHIMA, Yoko NABESHIMA, Chiaki ABE
-
Publication number: 20210100790Abstract: Provided is a drug superior for preventing and/or treating dementia. It contains a carbostyril derivative of the following formula (1) (wherein R is a cycloalkyl group, A is a lower alkyl group, and a single bond or a double bond is present between the 3-position and the 4-position of the carbostyril nucleus) and dihydroquercetin.Type: ApplicationFiled: December 18, 2020Publication date: April 8, 2021Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Tadamasa MATSUMOTO, Masafumi IHARA, Satoshi SAITO, Masanori FUKUSHIMA
-
Publication number: 20210047385Abstract: A nerve cell culture material including LASCol has the effect of successfully maintaining survival of the nerve cell. Furthermore, a therapeutic agent for nerve damage including LASCol can allow an endogenous nerve cell to infiltrate or proliferate actively in vivo, thereby enabling neurites to extend early and bind to each other, and has an effect on nerve damage, the effect being sufficient to improve a BBB score.Type: ApplicationFiled: January 31, 2019Publication date: February 18, 2021Applicants: KINKI UNIVERSITY, AINO UNIVERSITY, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Koichi MORIMOTO, Saori KUNII, Kenji KANEKIYO, Norihiko NAKANO, Chizuka IDE, Kaoru OMAE
-
Publication number: 20210046214Abstract: A therapeutic agent for intervertebral disc degeneration that contains LASCol obtained by enzymatically cleaving a terminus of collagen.Type: ApplicationFiled: January 31, 2019Publication date: February 18, 2021Applicants: NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY, KINKI UNIVERSITY, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Takashi YURUBE, Yoshiki TAKEOKA, Koichi MORIMOTO, Saori KUNII, Kaoru OMAE
-
Publication number: 20210038642Abstract: The present invention provides a cell preparation in which a proportion of leukocyte in a normal form and an undesired component containing at least one selected from the group consisting of erythrocyte, deformed cell, platelet and aggregate (undesired component count/leukocyte count) is not more than a predetermined value. The aforementioned predetermined value is preferably 37.0%. In addition, the cell preparation of the present invention can be utilized for the treatment of ischemic diseases such as cerebral infarction, myocardial infarction, limb ischemia, renal infarction, pulmonary infarction, splenic infarction, the intestinal infarction, Buerger disease, cerebrovascular dementia, diabetic nephropathy microangiopathy, diabetic cardiac failure and the like.Type: ApplicationFiled: March 5, 2019Publication date: February 11, 2021Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventor: Akihiko TAGUCHI
-
Publication number: 20200172969Abstract: The invention provides a method for predicting a differentiation potential of a pluripotent stem cell comprising measuring an expression level of CHD7 of the human pluripotent stem cell. The invention also provides a method for evaluating a medium for a human pluripotent stem cell comprising measuring an expression level of CHD7 of the pluripotent stem cell.Type: ApplicationFiled: June 4, 2018Publication date: June 4, 2020Applicant: FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBEInventors: Shin KAWAMATA, Takako YAMAMOTO, Chiemi TAKENAKA
-
Publication number: 20190358276Abstract: The present invention relates to a medicament for preventing and/or treating cognitive impairment and/or a neurodegenerative disease with accumulation of a prionoid, comprising a Sendai virus envelope as an active ingredient and combined application of the medicament and an immune checkpoint inhibitor.Type: ApplicationFiled: December 6, 2017Publication date: November 28, 2019Applicants: OSAKA UNIVERSITY, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, GENOMIDEA INC.Inventors: Yasufumi KANEDA, Masanori FUKUSHIMA, Toshihiro NAKAJIMA
-
Publication number: 20190343892Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: ApplicationFiled: July 11, 2019Publication date: November 14, 2019Applicants: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi YAMAHARA, Akihiko TAGUCHI, Toshihiro SOMA, Shunsuke OHNISHI, Akira KOBAYASHI
-
Patent number: 10441611Abstract: An object of the present invention is to provide a method for producing a mesenchymal stromal cell composition, comprising conveniently and aseptically separating high-purity amnion-derived MSCs by performing enzyme treatment only once. According to the present invention, the following are provided: a method for producing a mesenchymal stromal cell composition, comprising: performing enzyme treatment of an amnion with collagenase and thermolysin and/or dispase; and filtering the enzyme-treated amnion through a mesh; a method for producing a cryopreserved mesenchymal stromal cell composition; and a therapeutic agent comprising as an active ingredient the mesenchymal stromal cell composition for a disease selected from graft-versus-host disease, inflammatory bowel disease, systemic lupus erythematosus, liver cirrhosis, or radiation enteritis.Type: GrantFiled: August 18, 2014Date of Patent: October 15, 2019Assignees: NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, HYOGO COLLEGE OF MEDICINE, NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, KANEKA CORPORATIONInventors: Kenichi Yamahara, Akihiko Taguchi, Toshihiro Soma, Shunsuke Ohnishi, Akira Kobayashi